Your cousin?

A new type of prosthetic heart valve?

it!

Is your family so rebellious?

He knows that the artificial heart valve is still a backward technology in China, and your cousin has developed it alone? Oh my God!

"Yes, this is my cousin!" Ruan Bin pointed to Liu Xian not far away, who was chatting with a few experts at this time.

When Sun Chang and the others saw Liu Xian's age, they were all shocked.

, about thirty years old?

Could it be that this is the legendary demon family?

It looks amazing!

"Okay, well! Then on behalf of our group of students, I would like to express my gratitude to your institute! I believe that they will definitely learn from you well!" Sun Chang said with emotion.

"No thanks, Headmaster, it should be. I also believe in their strength! I will definitely be able to play a role in my research. Ruan Bin said with a smile.

But in his heart, he felt that this group of juniors and sisters were probably messing around here, in fact, he didn't need any powerful research scientists or anything, he just needed a group of people to fill up or something.

When the time comes, I can help with the help. Anyway, research data or something must be obtained from your own system, why do you think that new drugs or medical devices are so easy to develop?

Even if it can be developed, do you think you can crush other opponents in minutes?

So, he doesn't count on it!

This research institute of my own, in fact, is just an auxiliary tool.

The news that Ruan Bin had set up his own private research institute spread quickly, but people were paying attention to it, and they were looking forward to when Ruan Bin would come up with any new research results.

Moreover, at present, Ruan Bin's human clinical trial of KE has reached a little more than two years, and no one in those clinical volunteers has had any adverse reactions and problems.

In other words, this KE has slowly revealed its medicinal effect to the outside world!

Many outside media have been blowing nonsense, thinking that KE has a great chance of curing human cancer, and even has no side effects. At that time, Ruan Bin will be the first person to research that can cure cancer!

Yes, it's a cure!

......

After the establishment of the institute, Ruan Bin finally became idle.

So he planned to take a trip with Liu Xian and take a good look at this called Bairen Heart Product R&D Co., Ltd.!

According to Liu Xian, this company is currently the best company in the development and production of domestic artificial heart valves.

Since the other party was not in the magic capital, Ruan Bin and Liu Xian flew over directly.

on the plane.

"Tell me more about the company. Ruan Bin said to Liu Xian.

"Good!"

"Since its establishment in 2004, Parker Heart Products R&D Co., Ltd. has focused on the production and R&D of heart disease treatment devices, and the artificial biological heart valve developed by it is an important implantable device for the extension of life for 2 million rheumatic heart disease patients in China!"

However, the artificial biological heart valve product, which was expected to be high in the early years, could not be sold due to the long renewal period, and the company once faced a development dilemma. Solid R&D capabilities and rich product lines have made the company in a desperate situation: its neurobiological patches have received an enthusiastic response in the field of meningeal repair, with cumulative sales of more than 200,000 tablets since its launch, ranking fourth in China in terms of market share.

”

"At present, the main products of Parkman Heart Product R&D Co., Ltd. are: neurosurgery biological patch, cardiothoracic surgery biological patch, valvuloplastic ring and artificial biological heart valve, which are used in the field of surgical soft tissue repair, congenital heart disease value interventional treatment and heart valve replacement and repair, and the revenue of these products accounted for 39%, 33%, 14% and 9% of the total revenue in 2018. ”

"With the support of a rich product line, the company's performance is growing steadily: between 2016 and 2019, its revenue increased from 78.46 million yuan to 145 million yuan, with a compound annual growth rate of 22.7%, and its net profit reached 62.61 million yuan, a year-on-year increase of 87%. ”

"In this listing, the company will also use the 320 million yuan raised to expand production, and when the expansion project is completed, it will increase the production capacity of all products. ”

"Grasping all product lines in one go", the company's ambition is exposed. In fact, behind the seemingly "hand-holding" expansion plan, the company has long set its current development priorities in the field of heart valves and congenital heart disease treatment. ”

"The artificial biological heart valve is the company's first product, and it is also the earliest registered domestic product of artificial biological heart valve in China, and more than 10,000 have been replaced since its listing in 2005. However, due to the long "replacement" cycle, this product disappeared from the market in 2009 and did not return to the market until 2017, which also led to the loss of market share accumulated in the early stage. ”

"Due to the backwardness of domestic technology, this market has been monopolized by overseas companies, such as Edward, Metonli and San Judta, three imported brands occupy 90% of the domestic biovalve market share, of which Edwards is the leader of the domestic market, and its bovine pericardial bioprosthetic valve occupies 40% of the market share. At present, the market share of Parker Heart Product R&D Co., Ltd. in the field of biological valves in China is only 5%-6%!"

In 2017, the revenue of this product reached 4.24 million yuan, and by 2018, the revenue reached 10.44 million yuan, a year-on-year increase of 146%. So far, it has been clinically applied in 47 hospitals in China, and has been recognized by several large hospitals and other large tertiary hospitals......" Liu Xian patiently explained.

"Only 5%-6% market share?" Ruan Bin was speechless after hearing this market share.

It can also be seen from here that in the field of artificial heart valves, most of the domestic market is still occupied by foreign companies.

That is to say, 90% of artificial heart valves are imported!

And the annual revenue is only about 10 million, throwing out the cost or what?

I have to say that the development of this company is also quite difficult. This is still the largest artificial heart valve company in China.

What about the other small companies?

It's almost like waiting to die.

And the revenue of all products of the entire company is only more than 100 million a year, to be honest, his Fengyan Chinese medicine has this revenue in a week!

Thinking about it, it is indeed overwhelming to be crushed by foreign companies.